7月医疗领域融资亮点：科思明德完成数亿元A+轮融资，由腾讯领投

Group 1: Financing Highlights - Renasant Bio completed a $54.5 million seed round financing, focusing on small molecule therapies for polycystic kidney disease [1] - Synfini raised $8.9 million in seed round financing, specializing in small molecule drug development [1] - KaiMi Bio secured nearly 170 million RMB in Pre-A round financing, concentrating on innovative therapeutic vaccine development [1] Group 2: Additional Financing Activities - Qingxie Huah completed several tens of millions RMB in Pre-A round financing, focusing on orthopedic medical devices [2] - Keximingde raised several hundred million RMB in A+ round financing, led by Tencent, specializing in gastrointestinal endoscopy [2] - Centivax completed a $45 million Series A financing, focusing on universal immune platforms [2] Group 3: Recent Developments in Biotech - Jino Bio secured 50 million RMB in Series A financing, focusing on cell therapy drug development [3] - Aqtual raised $31 million in Series B financing, specializing in rheumatoid arthritis therapies [3] - Weimou Bio completed 140 million RMB in Series F financing, focusing on dry eye disease biopharmaceuticals [3] Group 4: Strategic and Pre-IPO Financing - Vili Zhibo completed $69 million in Pre-IPO financing, focusing on original antibody new drug development [4] - Chengge Bio secured over 100 million RMB in strategic financing, specializing in microbiota transplantation [4]